Publications by authors named "C Hoog"
Purpose: For the first time, three currently available 360° CZT-SPECT/CT cameras were compared under clinical conditions using phantom-based measurements.
Methods: A Tc- and a Lu-customized NEMA IEC body phantom were imaged with three different cameras, StarGuide (GE Healthcare), VERITON-CT versions 200 (V200) and 400 (V400) (Spectrum Dynamics Medical) under the same clinical conditions. Energy resolution and volumetric sensitivity were evaluated from energy spectra.
Article Synopsis
- Correct chromosome segregation is vital for genetic integrity, and the protein kinases Aurora B and C play a key role in regulating the attachment between kinetochores and microtubules during meiosis.
- During the second meiotic division in mouse oocytes, Aurora B and C were found to shift from the outer kinetochore to a central region between sister centromeres, and disrupting this localization led to chromosome misalignments.
- The study concluded that the central pool of Aurora B/C stabilizes chromosome alignment during metaphase II, while the outer kinetochores help correct any misalignments, together preventing chromosome segregation errors and abnormalities.
Long-term real-world data of ustekinumab in ulcerative colitis: the Stockholm Ustekinumab Study (STOCUSTE).
Eur J Gastroenterol Hepatol
December 2024
Background: Ustekinumab (UST) is an anti-interleukin-12/23 antibody used in the treatment of inflammatory bowel disease. This study includes patients treated at four hospitals in Stockholm to provide long-term real-world data.
Methods: Retrospective study including patients diagnosed with ulcerative colitis and treated with UST between the years 2019 and 2021.
Historically, dose selection of anticancer drugs has mainly been based on establishing the maximum tolerated dose in phase 1 clinical trials with a traditional 3 plus 3 design. In the era of targeted therapies and immune-modulating agents, this approach does not necessarily lead to selection of the most favourable dose. This strategy can introduce potentially avoidable toxicity or inconvenience for patients.
View Article and Find Full Text PDFBackground: Ustekinumab is used to treat inflammatory bowel disease mainly in patients failing anti-tumour necrosis factor (TNF)-agents.
Objectives: To provide real-world data in unselected patients with Crohn's disease (CD), treated with ustekinumab.
Design: Longitudinal retrospective study at four hospitals in Stockholm, Sweden.